NCT00477672 - A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | Biotech Hunter

Enrollment

298

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

July 31, 2009

Conditions

Parkinson's Disease Psychosis

Interventions

DRUG

Pimavanserin tartrate (ACP-103)

10 mg, tablet, once daily by mouth, 6 weeks

DRUG

Pimavanserin tartrate (ACP-103)

40 mg, tablet, once daily by mouth, 6 weeks

DRUG

Placebo

tablet, once daily by mouth, 6 weeks

Trial Locations (78)

1113

Sofia

5800

Pleven

7003

Rousse

9010

Varna

12401

Kingston

13385

Marseille

14618

Rochester

21005

Vinnytsia

23229

Richmond

28144

Salisbury

28806

Asheville

30912

Augusta

32209

Jacksonville

32610

Gainesville

33060

Pompano Beach

33136

Miami

33486

Boca Raton

33604

Pessac

33606

Tampa

33701

St. Petersburg

33952

Port Charlotte

34239

Sarasota

35059

Toulouse

37027

Brentwood

43210

Columbus

44093

Nantes

48034

Southfield

49684

Traverse City

61068

Kharkiv

62794

Springfield

63003

Clermont-Ferrand

67091

Strasbourg

78258

San Antonio

79010

Lviv

85013

Phoenix

85234

Gilbert

90746

Carson

91045

Luhansk

92697

Irvine

92708

Fountain Valley

94705

Berkeley

94805

Sunnyvale

98034

Kirkland

99204

Spokane

110060

New Dalhi

125284

Moscow

194044

Saint Petersburg

214018

Smolensk

400016

Mumbai

400036

Mumbai

411004

Pune

411030

Pune

420061

Kazan'

443095

Samara

500003

Hyderabad

530001

Visakhapatnam

560034

Bangalore

575001

Karnataka

575002

Mangalore

600006

Tamil Nadu

610014

Kirov

625020

Tamil Nadu

06810

Danbury

06824

Fairfield

04074

Scarborough

01655

Worcester

08755

Toms River

02886

Warwick

04080

Kiev

04114

Kiev

S75 2EP

Barnsley

BB3 2HH

Blackburn

BN2 5BE

Brighton

BH23 2JX

Dorset

NW3 2PF

London

NE4 6BE

Newcastle upon Tyne

NE29 8NH

North Shields

M6 8HD

Salford